Pathophysiology of tumor angiogenesis and its relevance in renal cell cancer

Anticancer Research

Volumn 19, Issue 2 C, 1999, Pages 1557-1561

  Strohmeyer, Dagmar ^a  

^a Department of Urology ^*  (Austria)

Author keywords

Angiogenesis; Renal cell cancer; Therapy

Indexed keywords

AE 941; ALPHA INTERFERON; ANGIOGENIC FACTOR; BATIMASTAT; CM 101; FUMAGILLOL CHLOROACETYLCARBAMATE; GROWTH FACTOR; INTERLEUKIN 12; MARIMASTAT; OCTREOTIDE; PENTOSAN POLYSULFATE; RETINOID; ROQUINIMEX; SEMAXANIB; TECOGALAN; THALIDOMIDE; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER TRANSPLANTATION; CELL TRANSFORMATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; GENETIC REGULATION; GROWTH RATE; HUMAN; KIDNEY CARCINOMA; META ANALYSIS; PRIORITY JOURNAL; SOLID TUMOR; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CAPILLARIES; CARCINOMA, RENAL CELL; CELL DIVISION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MELANOMA; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0033061404     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Atzpodien J, Hanninen EL; Kerchner H, Bodenstein H, Preudenschuh M, Rebmann U, Metzner B, Illiger HJ, Jakse G, Niesel T, Scholz HJ, Wilhelm S, Pielmeier T, Zakrzewski G, Blum G, Beier J, Müller GW, Duensing S, Anton P, Allhoff E, Jonas U, Poliwoda H: Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13: 497-501, 1995.
2. Bouck N, Stellmach V, Hsu SC: How tumors become angiogenic. Adv Cancer Res 69: 135-174, 1996.
3. Brooks PC, Montgomery AMP, Rosenfeld M, Hu T, Klein G, Cheresh DA: Intergrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164, 1994.
4. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder. Am J Pathol 143: 1255-1262, 1993.
5. Campell C: Advances in angiogenesis research: relevance to urological oncology. J Urol 158: 1663-1674, 1997.
6. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
7. Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61, 1989.
8. Fujimoto K, Ichimori Y, Kakizoe T: Increased serum levels of basic fibroblast growth factor in patients with renal cell cancer. Biochem Biophys Res Comm 180: 386-392, 1991.
9. Gimbrone MA, Leapman SB, Cotran RS, Folkman J: Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136: 261-276, 1972.
10. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marmt D: Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 270: 25915-25919, 1995.
11. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis supression. Natl Med 1: 149-153, 1995.
12. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, Kozai Y: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 51:6180-6184, 1991.
13. Imazono Y, Takebayashi Y, Nishiyama K, Suminori A, Kazutaka M, Yamada Y; Akiyama S-I, Yoshitada O: Correlation between Thymidine Phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 15(7): 2570-2578, 1997
14. Kieser A, Weich HA, Brandner G, Marmt D, Kωlch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9: 963-969, 1994.
15. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angio-genesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993.
16. MacLennan GT, Bostwick DG: Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology 46: 27-30, 1995.
17. Moghaddam A, Zhang H-T, Fan T-P D, Hu D-E, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R: Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92: 998-1002, 1995.
18. Morita T, Shinohara N, Tokue A: Antitumor effect of a synthetic analogue of fumagillin on murine renal carcinoma. Brit J Urol 74: 416-421, 1994.
19. Motzer RJ, Schwartz L, Law TM, Murphy Ba, Hoffman AD, Albino AP, Vlamis V, Nanus DM: Interferon alpha-2a and 13- cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vivo. J Clin Oncol 13: 1950-1957, 1995.
20. Nanus DM, Schmitz-Dräger B, Motzer RJ, Lee AC, Vlamis V, Cordon-Cardo C, Albino AP, Reuter VE: Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 85: 1597-1599, 1993.
21. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
22. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
23. Pepper MS, Ferrara N, Orci L, Montesano R: Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem and Biophys Res Commun 181: 902-906, 1991.
24. Siemeister G, Weindel K, Mohrs K, Barleon B. Marring-Baren G, Marme D: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56: 2299-2301, 1996.
25. Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE: The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. Am J Pathol 133: 419-423, 1988.
26. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54: 4233-4237, 1994.
27. Tannock I: Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res 30: 2470-2476, 1970.
28. Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702-6704, 1992.
29. Twardowski P and Gardishar WJ: Clinical trials of antiangiogenic agents. Current Oppinion in Oncology 9: 584-589, 1997.
30. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993.
31. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Nat Cancer Inst 84: 1875-1887, 1992.
32. Yoshino S, Mikio K, Koichi O: Prognostic significance of microvessel count in low stage renal cell carcinoma. Int J Urol 2: 156-160, 1994.